Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyzeRCTsin oncology

被引:18
|
作者
Ristl, Robin [1 ]
Ballarini, Nicolas M. [1 ]
Goette, Heiko [2 ]
Schueler, Armin [2 ]
Posch, Martin [1 ]
Koenig, Franz [1 ]
机构
[1] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[2] Merck Healthcare KGaA, Darmstadt, Germany
关键词
LOG-RANK TEST; FLEMING-HARRINGTON CLASS; SEQUENTIAL-TESTS; END-POINTS; WEIGHTS;
D O I
10.1002/pst.2062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed treatment effects, disease progression, treatment switchers or the presence of subgroups with differential treatment effects may challenge the assumption of proportional hazards. In practice, weighted logrank tests emphasizing either early, intermediate or late event times via an appropriate weighting function may be used to accommodate for an expected pattern of non-proportionality. We model these sources of non-proportional hazards via a mixture of survival functions with piecewise constant hazard. The model is then applied to study the power of unweighted and weighted log-rank tests, as well as maximum tests allowing different time dependent weights. Simulation results suggest a robust performance of maximum tests across different scenarios, with little loss in power compared to the most powerful among the considered weighting schemes and huge power gain compared to unfavorable weights. The actual sources of non-proportional hazards are not obvious from resulting populationwise survival functions, highlighting the importance of detailed simulations in the planning phase of a trial when assuming non-proportional hazards.We provide the required tools in a software package, allowing to model data generating processes under complex non-proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests.
引用
收藏
页码:129 / 145
页数:17
相关论文
共 50 条
  • [41] The Challenging Oncology Patient: The Substance Abuser and Treatment Issues
    Savage, Barbara
    Barrat-Gordon, Rene
    Bauer, Amy
    Grams, Jackie
    Grey, Clare
    Fireman, Karen
    Poole, Christa
    Schuermeyer, Isabel
    Dimitrov, Julie
    PSYCHO-ONCOLOGY, 2013, 22 : 49 - 49
  • [42] A patient with cancer and psoriasis - difficulties following oncology treatment
    Biedka, Marta
    Ziolkowska, Ewa
    Makarewicz, Roman
    Pietrusinska, Elzbieta
    Kubiak, Maria
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2009, 13 (06): : 339 - 342
  • [43] Treatment of uterine bleeding in the adolescent hematology/oncology patient
    Shackelford, DP
    Adcock, W
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1998, 15 (03) : 287 - 289
  • [44] Estimating Heterogeneous Treatment Effects and the Effects of Heterogeneous Treatments with Ensemble Methods
    Grimmer, Justin
    Messing, Solomon
    Westwood, Sean J.
    POLITICAL ANALYSIS, 2017, 25 (04) : 413 - 434
  • [45] DEVELOPING BEST PRACTICES FOR MANAGING TREATMENT SWITCHING IN THE DESIGN, CONDUCT, ANALYSIS, AND REPORTING OF ONCOLOGY DRUG CLINICAL TRIALS
    Conley, R. B.
    Al Naber, J.
    Messner, D. A.
    Henshall, C.
    Huang, C.
    Rosner, G. L.
    VALUE IN HEALTH, 2016, 19 (03) : A102 - A102
  • [46] Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting
    Sullivan, Thomas R.
    Latimer, Nicholas R.
    Gray, Jodi
    Sorich, Michael J.
    Salter, Amy B.
    Karnon, Jonathan
    VALUE IN HEALTH, 2020, 23 (03) : 388 - 396
  • [47] DELAYED ONSET OF TREATMENT IN A PATIENT WITH ULCERATIVE COLITIS: A CASE OF HOW DISPARITIES AFFECT HEALTHCARE ACCESS.
    Ibarra, Maria
    Guzman, Adalberto
    Ravichander, Benjamin
    Sangha, Lillian
    Mishagina, Irina
    INFLAMMATORY BOWEL DISEASES, 2023, 29 : S42 - S43
  • [48] Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method
    Zhang, Jin
    Chen, Cong
    STATISTICS IN MEDICINE, 2016, 35 (21) : 3690 - 3703
  • [49] Recurrent individual treatment assignment: a treatment policy approach to account for heterogeneous treatment effects
    Cornelisz, Ilja
    van Klaveren, Chris
    NPJ SCIENCE OF LEARNING, 2022, 7 (01)
  • [50] Recurrent individual treatment assignment: a treatment policy approach to account for heterogeneous treatment effects
    Ilja Cornelisz
    Chris van Klaveren
    npj Science of Learning, 7